{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:02:12Z","timestamp":1789603332435,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,16]]},"DOI":"10.7759\/cureus.116377","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:10:21Z","timestamp":1789600221000},"source":"Crossref","is-referenced-by-count":0,"title":["Chimeric Antigen Receptor T-cell (CAR-T) Therapy in Autoimmune Diseases: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Irviana A","family":"Molina-Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joselyn G","family":"Oliveros-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie D","family":"Molina-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anyuli P","family":"Guevara-Ostos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria F","family":"Blanco-Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig M","family":"Camacho-Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisana S","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00457-9","article-title":"Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK","volume":"401","author":"Conrad N","year":"2023","unstructured":"Conrad N, Misra S, Verbakel JY, et al.. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet. 2023, 401:1878-90. 10.1016\/S0140-6736(23)00457-9","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00668-1","article-title":"Global epidemiology of systemic lupus erythematosus","volume":"17","author":"Barber MR","year":"2021","unstructured":"Barber MR, Drenkard C, Falasinnu T, et al.. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021, 17:515-32. 10.1038\/s41584-021-00668-1","journal-title":"Nat Rev Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27094026","article-title":"Redefining difficult-to-treat systemic lupus erythematosus: biomarkers of molecular refractoriness beyond clinical failure","volume":"27","author":"Matusiewicz A","year":"2026","unstructured":"Matusiewicz A, Pa\u015b A, Wiktorzak S, Olesi\u0144ska M. Redefining difficult-to-treat systemic lupus erythematosus: biomarkers of molecular refractoriness beyond clinical failure. Int J Mol Sci. 2026, 27:4026. 10.3390\/ijms27094026","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1080\/1750743X.2025.2558348","article-title":"The potential of CAR T cells in autoimmune diseases","volume":"17","author":"Richter J","year":"2025","unstructured":"Richter J, Krusche M, Haase I, K\u00f6tter I, Kr\u00f6ger N. The potential of CAR T cells in autoimmune diseases. Immunotherapy. 2025, 17:937-52. 10.1080\/1750743X.2025.2558348","journal-title":"Immunotherapy"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000045698","article-title":"Advances and prospects of CAR-T cell therapy in autoimmune disease treatment","volume":"104","author":"Wang T","year":"2025","unstructured":"Wang T, Fu T, Xing G, Cai H, Tong Y. Advances and prospects of CAR-T cell therapy in autoimmune disease treatment. Medicine (Baltimore). 2025, 104:e45698. 10.1097\/MD.0000000000045698","journal-title":"Medicine (Baltimore)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S588071","article-title":"Anifrolumab in refractory oral manifestations in systemic lupus erythematosus: a case report and literature review","volume":"20","author":"Garmish O","year":"2026","unstructured":"Garmish O, Smiyan S, Komorovsky R, Bilozetskyi I. Anifrolumab in refractory oral manifestations in systemic lupus erythematosus: a case report and literature review. Biologics. 2026, 20:588071. 10.2147\/BTT.S588071","journal-title":"Biologics"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04430-6","article-title":"Resetting autoimmune disease with CAR cell therapies","volume":"32","author":"Schett G","year":"2026","unstructured":"Schett G, Xu H. Resetting autoimmune disease with CAR cell therapies. Nat Med. 2026, 32:2007-16. 10.1038\/s41591-026-04430-6","journal-title":"Nat Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103859","article-title":"Chimeric antigen receptor cell therapy: a revolutionary approach transforming cancer treatment to autoimmune disease therapy","volume":"24","author":"Wen R","year":"2025","unstructured":"Wen R, Li B, Wu F, et al.. Chimeric antigen receptor cell therapy: a revolutionary approach transforming cancer treatment to autoimmune disease therapy. Autoimmun Rev. 2025, 24:103859. 10.1016\/j.autrev.2025.103859","journal-title":"Autoimmun Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.117018","article-title":"B cell-targeted therapies in systemic lupus erythematosus: current status and perspectives","volume":"239","author":"Chen L","year":"2025","unstructured":"Chen L, Luo X, Yang Y, Du X, Zhang X, Luo D, Li K. B cell-targeted therapies in systemic lupus erythematosus: current status and perspectives. Biochem Pharmacol. 2025, 239:117018. 10.1016\/j.bcp.2025.117018","journal-title":"Biochem Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-025-03668-0","article-title":"CAR T cells as novel therapeutic strategy for multiple sclerosis and other neuroimmune disorders","volume":"23","author":"Samadzadeh S","year":"2025","unstructured":"Samadzadeh S, Szejko N, Hamadah Y, et al.. CAR T cells as novel therapeutic strategy for multiple sclerosis and other neuroimmune disorders. J Neuroinflammation. 2025, 23:35. 10.1186\/s12974-025-03668-0","journal-title":"J Neuroinflammation"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1613878","article-title":"CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon","volume":"16","author":"Wu D","year":"2025","unstructured":"Wu D, Xu-Monette ZY, Zhou J, Yang K, Wang X, Fan Y, Young KH. CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon. Front Immunol. 2025, 16:1613878. 10.3389\/fimmu.2025.1613878","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge C","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019, 4:5. 10.1186\/s41073-019-0064-8","journal-title":"Res Integr Peer Rev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-083122-044829","article-title":"B cell-directed therapy in autoimmunity","volume":"42","author":"Abeles I","year":"2024","unstructured":"Abeles I, Palma C, Meednu N, Payne AS, Looney RJ, Anolik JH. B cell-directed therapy in autoimmunity. Annu Rev Immunol. 2024, 42:103-26. 10.1146\/annurev-immunol-083122-044829","journal-title":"Annu Rev Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025413","article-title":"CAR T cells in autoimmunity: game changer or stepping stone?","volume":"145","author":"Mougiakakos D","year":"2025","unstructured":"Mougiakakos D, Meyer EH, Schett G. CAR T cells in autoimmunity: game changer or stepping stone?. Blood. 2025, 145:1841-9. 10.1182\/blood.2024025413","journal-title":"Blood"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1502712","article-title":"CD19 CAR-T cell therapy: a new dawn for autoimmune rheumatic diseases?","volume":"15","author":"Rangel-Pel\u00e1ez C","year":"2024","unstructured":"Rangel-Pel\u00e1ez C, Mart\u00ednez-Guti\u00e9rrez L, Trist\u00e1n-Manzano M, Callejas JL, Ortego-Centeno N, Mart\u00edn F, Mart\u00edn J. CD19 CAR-T cell therapy: a new dawn for autoimmune rheumatic diseases?. Front Immunol. 2024, 15:1502712. 10.3389\/fimmu.2024.1502712","journal-title":"Front Immunol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/biom12091303","article-title":"Co-stimulatory receptor signaling in CAR-T cells","volume":"12","author":"Honikel MM","year":"2022","unstructured":"Honikel MM, Olejniczak SH. Co-stimulatory receptor signaling in CAR-T cells. Biomolecules. 2022, 12:1303. 10.3390\/biom12091303","journal-title":"Biomolecules"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1688616","article-title":"Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model","volume":"12","author":"Singh AP","year":"2020","unstructured":"Singh AP, Zheng X, Lin-Schmidt X, et al.. Development of a quantitative relationship between CAR-affinity, antigen abundance, tumor cell depletion and CAR-T cell expansion using a multiscale systems PK-PD model. mAbs. 2020, 12:1688616. 10.1080\/19420862.2019.1688616","journal-title":"mAbs"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-026-02076-9","article-title":"CAR-T therapy for autoimmune rheumatic diseases: navigating clinical frontiers between breakthroughs and uncertainties","volume":"26","author":"Cheng J","year":"2026","unstructured":"Cheng J, Zhang X, Fan Y, Zhang Z. CAR-T therapy for autoimmune rheumatic diseases: navigating clinical frontiers between breakthroughs and uncertainties. Clin Exp Med. 2026, 26:177. 10.1007\/s10238-026-02076-9","journal-title":"Clin Exp Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller F","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, et al.. CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up. N Engl J Med. 2024, 390:687-700. 10.1056\/NEJMoa2308917","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251910511","article-title":"CAR-T-cell therapy for systemic lupus erythematosus: a comprehensive overview","volume":"25","author":"Abdalhadi HM","year":"2024","unstructured":"Abdalhadi HM, Chatham WW, Alduraibi FK. CAR-T-cell therapy for systemic lupus erythematosus: a comprehensive overview. Int J Mol Sci. 2024, 25:10511. 10.3390\/ijms251910511","journal-title":"Int J Mol Sci"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1879668","article-title":"CAR-based cellular therapy for refractory systemic lupus erythematosus: an overlap-controlled systematic review","volume":"17","author":"Li SG","year":"2026","unstructured":"Li SG, Yu R, Zhang L, et al.. CAR-based cellular therapy for refractory systemic lupus erythematosus: an overlap-controlled systematic review. Front Immunol. 2026, 17:1879668. 10.3389\/fimmu.2026.1879668","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2025-005866","article-title":"Key considerations for advancing chimeric antigen receptor (CAR) T-cell therapy for systemic lupus erythematosus (SLE): a multi-partner\/disciplinary working group perspective","volume":"11","author":"Hsieh EW","year":"2025","unstructured":"Hsieh EW, Chung JB, Amin A, et al.. Key considerations for advancing chimeric antigen receptor (CAR) T-cell therapy for systemic lupus erythematosus (SLE): a multi-partner\/disciplinary working group perspective. RMD Open. 2025, 11:005866. 10.1136\/rmdopen-2025-005866","journal-title":"RMD Open"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2026.104090","article-title":"Chimeric antigen receptor-based cellular therapy in autoimmune diseases: a systematic review and meta-analysis of clinical, serological and safety outcomes","volume":"25","author":"Wong HJ","year":"2026","unstructured":"Wong HJ, Lee AR, Yap QV, Chan E, Schett G, Tay SH. Chimeric antigen receptor-based cellular therapy in autoimmune diseases: a systematic review and meta-analysis of clinical, serological and safety outcomes. Autoimmun Rev. 2026, 25:104090. 10.1016\/j.autrev.2026.104090","journal-title":"Autoimmun Rev"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/art.43219","article-title":"Differences in dynamics of specific antinuclear antibodies and their susceptibility to B cell-targeting treatment in patients with systemic lupus erythematosus","volume":"77","author":"van Dooren HJ","year":"2025","unstructured":"van Dooren HJ, van Schaik M, Dorj\u00e9e AL, et al.. Differences in dynamics of specific antinuclear antibodies and their susceptibility to B cell-targeting treatment in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2025, 77:1560-72. 10.1002\/art.43219","journal-title":"Arthritis Rheumatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"Auth J","year":"2025","unstructured":"Auth J, M\u00fcller F, V\u00f6lkl S, et al.. CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series. Lancet Rheumatol. 2025, 7:83-93. 10.1016\/S2665-9913(24)00282-0","journal-title":"Lancet Rheumatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang X","year":"2024","unstructured":"Wang X, Wu X, Tan B, et al.. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell. 2024, 187:4890-904.e9. 10.1016\/j.cell.2024.06.027","journal-title":"Cell"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01671-X","article-title":"Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China","volume":"406","author":"Gao J","year":"2026","unstructured":"Gao J, Li M, Sun M, et al.. Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China. Lancet. 2026, 406:2968-79. 10.1016\/S0140-6736(25)01671-X","journal-title":"Lancet"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2026.101226","article-title":"Safety and efficacy of low-dose, cord blood-derived CD19 CAR-NK cells with 4-1BB co-stimulation in refractory systemic lupus erythematosus","volume":"7","author":"Zeng Z","year":"2026","unstructured":"Zeng Z, Lei W, Deng W, et al.. Safety and efficacy of low-dose, cord blood-derived CD19 CAR-NK cells with 4-1BB co-stimulation in refractory systemic lupus erythematosus. Med. 2026, 7:101226. 10.1016\/j.medj.2026.101226","journal-title":"Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04185-6","article-title":"CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial","volume":"32","author":"M\u00fcller F","year":"2026","unstructured":"M\u00fcller F, Hagen M, Wirsching A, et al.. CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial. Nat Med. 2026, 32:1142-51. 10.1038\/s41591-025-04185-6","journal-title":"Nat Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett G","year":"2023","unstructured":"Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet. 2023, 402:2034-44. 10.1016\/S0140-6736(23)01126-1","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(24)00240-6","article-title":"Barriers to CAR T-cell therapy in rheumatology","volume":"7","author":"Lungova K","year":"2025","unstructured":"Lungova K, Putman M. Barriers to CAR T-cell therapy in rheumatology. Lancet Rheumatol. 2025, 7:212-6. 10.1016\/S2665-9913(24)00240-6","journal-title":"Lancet Rheumatol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224875","article-title":"CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury","volume":"83","author":"Lodka D","year":"2024","unstructured":"Lodka D, Zschummel M, Bunse M, et al.. CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury. Ann Rheum Dis. 2024, 83:499-507. 10.1136\/ard-2023-224875","journal-title":"Ann Rheum Dis"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-024-05772-5","article-title":"Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review","volume":"45","author":"Kattamuri L","year":"2025","unstructured":"Kattamuri L, Mohan Lal B, Vojjala N, Jain M, Sharma K, Jain S, Al Hadidi S. Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review. Rheumatol Int. 2025, 45:18. 10.1007\/s00296-024-05772-5","journal-title":"Rheumatol Int"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf290","article-title":"CAR-T cells targeting CD19 for the treatment of ANCA vasculitis","volume":"18","author":"Lodka D","year":"2025","unstructured":"Lodka D, Schreiber A. CAR-T cells targeting CD19 for the treatment of ANCA vasculitis. Clin Kidney J. 2025, 18:ii35-46. 10.1093\/ckj\/sfaf290","journal-title":"Clin Kidney J"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-025-01272-3","article-title":"CAR T cell therapy for children with rheumatic disease: the time is now","volume":"21","author":"Wobma H","year":"2025","unstructured":"Wobma H, Ardoin SP, Bonifant CL, et al.. CAR T cell therapy for children with rheumatic disease: the time is now. Nat Rev Rheumatol. 2025, 21:494-506. 10.1038\/s41584-025-01272-3","journal-title":"Nat Rev Rheumatol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-025-09113-7","article-title":"CAR T cell therapy for rheumatoid arthritis","volume":"68","author":"Freeley M","year":"2025","unstructured":"Freeley M. CAR T cell therapy for rheumatoid arthritis. Clin Rev Allergy Immunol. 2025, 68:100. 10.1007\/s12016-025-09113-7","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2040","article-title":"Model-based cellular kinetic analysis of chimeric antigen receptor-T cells in humans","volume":"109","author":"Liu C","year":"2021","unstructured":"Liu C, Ayyar VS, Zheng X, et al.. Model-based cellular kinetic analysis of chimeric antigen receptor-T cells in humans. Clin Pharmacol Ther. 2021, 109:716-27. 10.1002\/cpt.2040","journal-title":"Clin Pharmacol Ther"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno JN","year":"2024","unstructured":"Brudno JN, Kochenderfer JN. Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol. 2024, 21:501-21. 10.1038\/s41571-024-00903-0","journal-title":"Nat Rev Clin Oncol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.03.011","article-title":"Cytokine release syndrome and neurotoxicity following CD19 CAR-T in B-cell lymphoma","volume":"31","author":"Shouval R","year":"2025","unstructured":"Shouval R, Strouse C, Kim S, et al.. Cytokine release syndrome and neurotoxicity following CD19 CAR-T in B-cell lymphoma. Transplant Cell Ther. 2025, 31:419-33. 10.1016\/j.jtct.2025.03.011","journal-title":"Transplant Cell Ther"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines MR","year":"2023","unstructured":"Hines MR, Knight TE, McNerney KO, et al.. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplant Cell Ther. 2023, 29:438.e1-e16. 10.1016\/j.jtct.2023.03.006","journal-title":"Transplant Cell Ther"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1007\/s44313-026-00145-2","article-title":"Infectious complications after CAR T-cell therapy: mechanisms, risk stratification, and prevention","volume":"61","author":"Lee E","year":"2026","unstructured":"Lee E, Lee JH, Kim HR, et al.. Infectious complications after CAR T-cell therapy: mechanisms, risk stratification, and prevention. Blood Res. 2026, 61:30. 10.1007\/s44313-026-00145-2","journal-title":"Blood Res"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.01.018","article-title":"Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab","volume":"130","author":"Athni TS","year":"2023","unstructured":"Athni TS, Barmettler S. Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab. Ann Allergy Asthma Immunol. 2023, 130:699-712. 10.1016\/j.anai.2023.01.018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1841031","article-title":"Optimizing ciltacabtagene autoleucel outcomes: real-world experience and best practices from a single academic center","volume":"16","author":"Shune LO","year":"2026","unstructured":"Shune LO, Mahmoudjafari Z, McGuirk JP. Optimizing ciltacabtagene autoleucel outcomes: real-world experience and best practices from a single academic center. Front Oncol. 2026, 16:1841031. 10.3389\/fonc.2026.1841031","journal-title":"Front Oncol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2026.2627057","article-title":"From technological iteration to clinical breakthrough: advances of CAR-T cell therapy in autoimmune diseases","volume":"58","author":"Yu B","year":"2026","unstructured":"Yu B, Xu J, Cui Y. From technological iteration to clinical breakthrough: advances of CAR-T cell therapy in autoimmune diseases. Ann Med. 2026, 58:2627057. 10.1080\/07853890.2026.2627057","journal-title":"Ann Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000002354","article-title":"Systematic review of chimeric antigen receptor T-cell therapy in autoimmune diseases","volume":"32","author":"Hershkowitz N","year":"2026","unstructured":"Hershkowitz N, Andrzejczyk A, DeStefano V, Schuster M, Yao Q. Systematic review of chimeric antigen receptor T-cell therapy in autoimmune diseases. J Clin Rheumatol. 2026, 32:e173-81. 10.1097\/RHU.0000000000002354","journal-title":"J Clin Rheumatol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.106661","article-title":"The price of remission: modeling the total financial burden, quality-of-life impairment, and healthcare dependence in lupus compared with chimeric antigen receptor (CAR) T-cell therapy","volume":"18","author":"Kumar K","year":"2026","unstructured":"Kumar K, Kim K. The price of remission: modeling the total financial burden, quality-of-life impairment, and healthcare dependence in lupus compared with chimeric antigen receptor (CAR) T-cell therapy. Cureus. 2026, 18:e106661. 10.7759\/cureus.106661","journal-title":"Cureus"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2026.2626239","article-title":"Time to access matters: patient gains from faster CAR T-cell reimbursement in Europe","volume":"29","author":"Tan YZ","year":"2026","unstructured":"Tan YZ, Breislin E, Woods M, et al.. Time to access matters: patient gains from faster CAR T-cell reimbursement in Europe. J Med Econ. 2026, 29:481-97. 10.1080\/13696998.2026.2626239","journal-title":"J Med Econ"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1002\/adma.74058","article-title":"Nanomaterials drive in vivo CAR immune cells engineering","volume":"38","author":"Luo M","year":"2026","unstructured":"Luo M, Liao K, Chang J, Xie J, Liang XJ, Lei Q, Guo W. Nanomaterials drive in vivo CAR immune cells engineering. Adv Mater. 2026, 38:e74058. 10.1002\/adma.74058","journal-title":"Adv Mater"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2026.03.033","article-title":"In situ generation of EBNA1 CAR-T cells eradicates antigen specific auto-immune B cells for multiple sclerosis treatment","volume":"16","author":"Shi C","year":"2026","unstructured":"Shi C, Han M, Yang H, et al.. In situ generation of EBNA1 CAR-T cells eradicates antigen specific auto-immune B cells for multiple sclerosis treatment. Acta Pharm Sin B. 2026, 16:4676-91. 10.1016\/j.apsb.2026.03.033","journal-title":"Acta Pharm Sin B"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/532829-chimeric-antigen-receptor-t-cell-car-t-therapy-in-autoimmune-diseases-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:10:22Z","timestamp":1789600222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/532829-chimeric-antigen-receptor-t-cell-car-t-therapy-in-autoimmune-diseases-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":49,"URL":"https:\/\/doi.org\/10.7759\/cureus.116377","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,16]]}}}